Fig. 1

Association between post-diagnostic use (dispensation of ≥ 270 defined daily doses after diagnosis) of low-dose aspirin, compared to no use, and breast cancer-specific survival, Norway 2004–2017, by age, molecular subtype, stage, and use of chemotherapy. Abbreviation Low-dose aspirin (LDA), breast cancer (BC), person-years (PY), hazard ratio (HR), confidence interval (CI), oestrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), triple negative breast cancer (TNBC). ^aAdjusted for age at diagnosis, education, marital status, number of children, country of origin, stage, molecular subtype, histology, and post-diagnostic use of concomitant medications (statins, metformin, non-aspirin antiplatelets, non-metformin antidiabetics, non-steroidal anti-inflammatory drugs, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics). The stratified estimates are adjusted for all variables except for the specific stratification variable